BHVN•benzinga•
Biohaven Initiates Global Phase 2/3 Study Of First-In-Clinic, Orally-Administered, Brain-Penetrant, And Highly Selective TYK2/JAK1 Inhibitor, BHV-8000, For PD Treatment
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 29, 2025 by benzinga